Current Problems of Psychiatry
June 24, 2024
Karol Kasprzak, Agnieszka Dyzma-Kasprzak, Z. Wingralek et al.
Introduction: Narcolepsy (NT) can manifest as excessive daytime sleepiness (EDS), cataplexy, hypnagogic (HHG) and hypnopompic (HHP) hallucinations, sleep paralysis, orgasmolepsy – all of which may affect patients' functioning. The aim of the study was to determine the impact of NT, specific sexual dysfunctions and drugs used in NT on sex life. Materials and methods: A narrative review was...
Neuroscience Letters
June 21, 2024
Carlos M Contreras, Ana G Gutiérrez-García
4 citations
Ketamine is a dissociative anesthetic that has been proposed to be a useful alternative in cases of a poor response to other treatments in patients with depression. Remarkably, beneficial clinical actions of ketamine are detected once its psychotropic actions disappear. Therefore, clinical actions may occur independently of dose. Most current studies focus on actions of ketamine on neurotrophic...
Journal of Psychoactive Drugs
June 21, 2024
Peter Kenneth Gillman, Brian S. Barnett, Curtis J. Koons et al.
9 citations
Data on medication interactions with psychedelics are limited. Here we present what may be the first published report of a hypertensive emergency following the combination of psilocybin mushrooms with a monoamine oxidase inhibitor (MAOI). A 42-year-old man with treatment-resistant major depressive disorder took 1 g of Psilocybe cubensis mushrooms, while prescribed tranylcypromine,...
medRxiv
June 20, 2024
Dimy Fluyau, Vasanth Kattalai Kailasam, Neelambika Revadigar
preprint
Abstract Background Hallucinogens attract research as alternatives to the commonly used medications to treat major depressive and anxiety disorders. Aims Assess hallucinogens’ efficacy for managing depressive and anxiety symptoms and evaluate their safety profiles. Method In five databases, we searched for randomized controlled trials of hallucinogens targeting depressive and anxiety symptoms....
Frontiers in Human Neuroscience
June 19, 2024
Giuseppe Pasculli, Pierpaolo Busan, Eric S. Jackson et al.
5 citations
Developmental stuttering (DS) is a neurodevelopmental speech-motor disorder characterized by symptoms such as blocks, repetitions, and prolongations. Persistent DS often has a significant negative impact on quality of life, and interventions for it have limited efficacy. Herein, we briefly review existing research on the neurophysiological underpinnings of DS -specifically, brain metabolic and...
June 17, 2024
Richard J. Zeifman
1 citation
Although psilocybin therapy is currently receiving attention as a novel intervention for a wide range of mental health concerns, limited research has examined the underlying psychological mechanisms (i.e., how) through which psilocybin therapy may bring about positive therapeutic changes. Qualitative research highlights the role of reductions in experiential avoidance (i.e., avoidance or...
Neuroscience of Consciousness
June 15, 2024
Paolo Cardone, Naji Alnagger, Jitka Annen et al.
16 citations
Modern medicine has been shaken by the surge of psychedelic science that proposes a new approach to mitigate mental disorders, such as depression and post-traumatic stress disorder. Clinical trials to investigate whether psychedelic substances can treat psychiatric conditions are now underway, yet less discussion gravitates around their use in neurological disorders due to brain injury. One...
ACS Pharmacology & Translational Science
June 14, 2024
Richard A Glennon, Małgorzata Dukat
21 citations
1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI, or DOX where X = -I) was first synthesized in 1973 in a structure-activity study to explore the effect of various aryl substituents on the then newly identified, and subsequently controlled, hallucinogenic agent 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM, or DOX where X = -CH3). Over time, DOI was found to be a serotonin (5-HT)...
UNC Libraries
June 12, 2024
D Mwende . Muthoni, Roth B.l
Psychedelic drugs including psilocybin, N,Nʹ-dimethyltryptamine (DMT) and lysergic acid diethylamide (LSD) are undergoing a renaissance as potentially useful drugs for various neuropsychiatric diseases, with a rapid onset of therapeutic activity. Notably, phase II trials have shown that psilocybin can produce statistically significant clinical effects following one or two administrations in...
UNC Libraries
June 12, 2024
Diberto J.f, Roth B.l
Psilocybin has emerged as a potentially rapidly acting antidepressant with enduring actions. In this issue of Neuron, Shao et al. (2021) show that psilocybin quickly induces dendritic spine formation in cortical layer V pyramidal neurons. These results provide a potential cellular substrate for psilocybin's therapeutic actions.